Skip to main content
OpenTrials
Completed

NCT Number: NCT05687474

Baby Detect : Genomic Newborn Screening

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple blood test, rare genetic conditions can be easily detected, and the early start of transformative treatment will help avoid severe disabilities and increase the quality of life.

Baby Detect Project is an innovative NBS program using a panel of target sequencing that aims to identify 126 treatable severe early onset genetic diseases at birth caused by 361 genes. The list of diseases has been established in close collaboration with the Paediatricians of the University Hospital in Liege. The investigators use dedicated dried blood spots collected between the first day and 28 days of life of babies, after a consent sign by parents.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Congenital Adrenal Hyperplasia 3-Hydroxy 3-Methyl Glutaric Aciduria 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency 3-Hydroxy-3-Methylglutaryl-CoA Synthase 2 Deficiency Abnormalities, Multiple Acidemia, isovaleric Aciduria, Argininosuccinic Acyl-CoA Dehydrogenase Family, Member 9, Deficiency of Adrenal Gland Diseases Adrenal Hyperplasia, Congenital Adrenal Insufficiency Adrenogenital Syndrome Adrenoleukodystrophy Albinism Alpha 1-Antitrypsin Deficiency Alpha-Thalassemia Alport Syndrome Amino Acid Metabolism, Inborn Errors Andersen Syndrome Andersen Tawil Syndrome Anemia Anemia, Aplastic Anemia, Diamond-Blackfan Anemia, Hemolytic Anemia, Hemolytic, Congenital Anemia, Hypoplastic, Congenital Anemia, Sickle Cell Argininemia Argininosuccinic Aciduria Aromatic L-amino Acid Decarboxylase Deficiency Aromatic amino acid decarboxylase deficiency Arrhythmias, Cardiac Aspartylglucosaminuria Ataxia With Vitamin E Deficiency Autoimmune Diseases Autoimmune Diseases of the Nervous System Avitaminosis Basal Ganglia Diseases Basal ganglia disease, biotin-responsive Beta Ketothiolase Deficiency Biotinidase Deficiency Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Bone Diseases Bone Diseases, Developmental Bone Diseases, Endocrine Bone Diseases, Metabolic Bone Marrow Diseases Bone Marrow Failure Disorders Brain Diseases Brain Diseases, Metabolic Brain Diseases, Metabolic, Inborn Brain Dopamine-Serotonin Vesicular Transport Disease Branched-Chain Keto Acid Dehydrogenase Kinase Deficiency Brown-Vialetto-Van Laere syndrome Calcium Metabolism Disorders Carbamoyl Phosphate Synthase 1 Deficiency Carbamoyl-Phosphate Synthase I Deficiency Disease Carbohydrate Metabolism, Inborn Errors Cardiac Conduction System Disease Cardiomyopathy, Familial Hypertrophic, 4 Cardiovascular Abnormalities Cardiovascular Diseases Carnitine Acylcarnitine Translocase Deficiency Carnitine Palmitoyltransferase Deficiency 1 Carnitine Palmitoyltransferase Deficiency 2 Carnitine palmitoyl transferase 1A deficiency Carnitine palmitoyl transferase 2 deficiency Carnitine-Acylcarnitine Translocase Deficiency Catecholaminergic Polymorphic Ventricular Tachycardia Central Nervous System Diseases Cerebral Folate Transport Deficiency Charcot-Marie-Tooth Disease Charcot-Marie-Tooth Disease, Type 6C Chediak-Higashi Syndrome Cholestasis, progressive familial intrahepatic 1 Cholesterol Ester Storage Disease Chronic Disease Chronic Granulomatous Disease Citrullinemia Citrullinemia 1 Citrullinemia Type II Coagulation Protein Disorders Cobalamin Deficiency Collagen Diseases Combined Pituitary Hormone Deficiency Congenital Abnormalities Congenital Bone Marrow Failure Syndromes Congenital Hyperinsulinism Congenital Hypothyroidism Congenital Myasthenic Syndrome Congenital Nephrotic Syndrome, Finnish Type Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Creatine Deficiency Syndrome Crigler-Najjar Syndrome Cystic Fibrosis Cystinosis Cytopenia DNA Repair-Deficiency Disorders Deficiency Diseases Deficiency of GOT2 Deficit in Anterior Pituitary Function and Variable Immunodeficiency Demyelinating Diseases Diabetes Insipidus Diabetes Insipidus, Nephrogenic Diabetes Mellitus Diabetes Mellitus, Type 2 Diamond Blackfan Anemia Digestive System Diseases Disaccharide Intolerance I Disease Attributes Disorders of Sex Development Dopamine Beta Hydroxylase Deficiency Dwarfism Dyslipidemias Dystonia, Dopa-Responsive, due to Sepiapterin Reductase Deficiency Emphysema Endocrine System Diseases Exocrine Pancreatic Insufficiency Eye Diseases Eye Diseases, Hereditary Eye Neoplasms Familial Chylomicronemia Familial Hemophagocytic Lymphocytosis Familial Hyperinsulinemic Hypoglycemia 1 Familial Hypertrophic Cardiomyopathy Type 4 Familial Hypophosphatemic Rickets Fanconi Anemia Fanconi Bickel Syndrome Fanconi Syndrome Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Fructose Intolerance Fructose Metabolism, Inborn Errors Fructose-1,6-Diphosphatase Deficiency Fructosemia GLUT1 Deficiency Syndrome Galactosemias Gaucher Disease Gaucher Disease, Type 1 Genetic Diseases, Inborn Genetic Diseases, X-Linked Glucose 6 Phosphate Dehydrogenase Deficiency Glucose Galactose Malabsorption Glucose Metabolism Disorders Glucose-Galactose Malabsorption Glucosephosphate Dehydrogenase Deficiency Glutaric Acidemia I Glycine Encephalopathy Glycogen Storage Disease Glycogen Storage Disease Type II Glycogen Storage Disease XIV Gonadal Disorders Granulomatous Disease, Chronic Griscelli Syndrome HHH syndrome Hair Diseases Heart Defects, Congenital Heart Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemoglobinopathies Hemophilia A Hemophilia B Hemorrhagic Disorders Hepatolenticular Degeneration Hereditary Central Nervous System Demyelinating Diseases Hereditary Hyperekplexia Hereditary Nephrogenic Diabetes Insipidus Hereditary Retinoblastoma Hereditary Sensory and Motor Neuropathy Heredodegenerative Disorders, Nervous System Histiocytosis Histiocytosis, Non-Langerhans-Cell Holocarboxylase Synthetase Deficiency Homocystinuria Hyperargininemia Hyperbilirubinemia, Hereditary Hyperglycinemia, Nonketotic Hyperhomocysteinemia Hyperinsulinism Hyperlipidemias Hyperlipoproteinemia Type I Hyperlipoproteinemias Hypermethioninemia Hyperornithinemia-Hyperammonemia-Homocitrullinuria Hyperoxaluria Hyperoxaluria, Primary Hypoglycemia Hypophosphatasia, Infantile Hypophosphatemia Hypophosphatemia, Familial Hypothyroidism Immune System Diseases Immunologic Deficiency Syndromes Infant, Newborn, Diseases Inflammatory Bowel Disease 25, Autosomal Recessive Intellectual Disability Isolated Methylmalonic Acidemia Isovaleric Acidemia Jervell-Lange Nielsen Syndrome Kidney Diseases Late-Infantile Neuronal Ceroid Lipofuscinosis Leukocyte Disorders Leukodystrophy, Metachromatic Leukoencephalopathies Leukopenia Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipidoses Lipomatosis Liver Diseases Long QT Syndrome Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency Lung Diseases Lymphatic Diseases Lymphohistiocytosis, Hemophagocytic Lymphopenia Lysosomal Acid Lipase Deficiency Lysosomal Storage Diseases Lysosomal Storage Diseases, Nervous System Male Urogenital Diseases Malnutrition Malonic Acidemia Malonic aciduria Maple Syrup Urine Disease Maturity Onset Diabetes of the Young Medium Chain Acyl CoA Dehydrogenase Deficiency Menkes Disease Menkes Kinky Hair Syndrome Metabolic Diseases Metabolism, Inborn Errors Metachromatic Leukodystrophy Metal Metabolism, Inborn Errors Methylmalonic acidemia Mitochondrial Diseases Movement Disorders Mucinoses Mucopolysaccharidoses Mucopolysaccharidosis I Mucopolysaccharidosis II Mucopolysaccharidosis IV Mucopolysaccharidosis IV A Mucopolysaccharidosis VI Mucopolysaccharidosis VII Multiple Carboxylase Deficiency Musculoskeletal Diseases Myasthenic Syndromes, Congenital N Acetyl Glutamate Synthetase Deficiency Neonatal-onset citrullinemia type 2 Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Nephritis Nephritis, Hereditary Nephrosis, congenital Nervous System Diseases Nervous System Malformations Neurobehavioral Manifestations Neurodegeneration Due To Cerebral Folate Transport Deficiency Neurodegenerative Diseases Neuroectodermal Tumors Neurologic Manifestations Neuromuscular Diseases Neuromuscular Junction Diseases Neuronal Ceroid-Lipofuscinoses Neutropenia, Severe Congenital, Autosomal Recessive 3 Nutrition Disorders Nutritional and Metabolic Diseases Ornithine Carbamoyltransferase Deficiency Disease Ornithine Transcarbamylase Deficiency Pancreatic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Peroxisomal Disorders Phagocyte Bactericidal Dysfunction Phenylalanine Hydroxylase Deficiency Phenylketonurias Phosphoglucomutase 1 Deficiency Phosphoglycerate Dehydrogenase Deficiency Phosphorus Metabolism Disorders Phosphoserine Aminotransferase Deficiency Phosphoserine Phosphatase Deficiency Pituitary Hormone Deficiency, Combined Polymorphic Catecholaminergic Ventricular Tachycardia Polyneuropathies Pompe Disease Primary Hyperoxaluria Primary Immunodeficiency Diseases Progressive Familial Intrahepatic Cholestasis Propionic Acidemia Pseudohypoaldosteronism Pseudohypoaldosteronism Type 1 Pseudohypoaldosteronism, Type II Pyridoxamine 5-Prime-Phosphate Oxidase Deficiency Pyridoxine-5'-Phosphate Oxidase Deficiency Pyridoxine-Dependent Epilepsy Red-Cell Aplasia, Pure Renal Tubular Transport, Inborn Errors Respiratory Tract Diseases Retinal Diseases Retinal Neoplasms Retinoblastoma Riboflavin Deficiency Riboflavin Transporter Deficiency Rickets Rickets, Hypophosphatemic S-Adenosylhomocysteine Hydrolase Deficiency Segawa Syndrome, Autosomal Recessive Sepiapterin Reductase Deficiency Severe Combined Immune Deficiency Severe Combined Immunodeficiency Severe Congenital Neutropenia Shwachman-Diamond Syndrome Sickle Cell Disease Skin Diseases Skin and Connective Tissue Diseases Smith-Lemli-Opitz Syndrome Sphingolipidoses Spinal Cord Diseases Steroid Metabolism, Inborn Errors Stiff-Person Syndrome Subcutaneous Emphysema Succinyl-CoA:3-oxoacid CoA transferase deficiency Succinyl-Coa:3-Ketoacid Coa-Transferase Deficiency Sucrase-isomaltase deficiency, congenital Sulfatidosis Systemic Primary Carnitine Deficiency Systemic carnitine deficiency Tachycardia Tachycardia, Ventricular Thalassemia Thiamine Metabolism Dysfunction Syndrome 2 Thiamine Metabolism Dysfunction Syndrome 4 (Bilateral Striatal Degeneration and Progressive Polyneuropathy Type) Thiamine Metabolism Dysfunction Syndrome 5 (Episodic Encephalopathy Type) Thiamine-Responsive Megaloblastic Anemia Thyroid Diseases Timothy Syndrome Transcobalamin Deficiency Trifunctional Protein Deficiency With Myopathy And Neuropathy Tyrosinemia, Type I Tyrosinemias Urea Cycle Disorders, Inborn Urogenital Abnormalities Urogenital Diseases Urologic Diseases Very Long Chain Hydroxy Acyl Dehydrogenase Deficiency Vitamin B 12 Deficiency Vitamin B Deficiency Vitamin D Deficiency Wilson Disease Wiskott-Aldrich Syndrome Wolman Disease X Linked Hypophosphatemia X-Linked Intellectual Disability

Age range

Up to 28 day

Sex eligibility

All sexes

Study type

Observational

Primary location

CRMN, Hôpital La Citadelle

Liège, Wallonia, 4000, Belgium

About this study

Every year, thousands of children around the world are born with rare genetic diseases leading to death or lifelong disability. With technological advancements in the field of genetics and medicine, the rate of introduction of treatments for these rare conditions has grown remarkably.

However, timing is of great importance for medication administration. The benefit that can be measured in a patient who has already suffered from a long irreversible degenerative disorder is small and, sometimes, it hardly justifies the cost and the burden of the treatment. Early diagnosis is, thus, of primary importance both to obtain the best effect of the innovative medications and to accelerate their development.

The investigators are pioneered in the field of genetic newborn screening (NBS) in rare diseases by funding, designing, and leading an innovative genetic NBS program initiated in March 2018 in Southern Belgium for Spinal Muscular Atrophy (SMA) that allowed, so far, for 11 children to be detected and treated early and avoid the terrible fate of the disease. The program was disseminated in 17 countries and included public dissemination and health-economic analysis since the very beginning [1]. (www.facebook.com/sunmayariseonsma).

Drawing upon our experience with SMA screening, the investigators have designed a project to screen up to 40,000 newborns/year progressively in 3 years for virtually all the rare diseases that can benefit from treatment or a pre-symptomatic clinical trial.

The methodology of Baby Detect includes sequencing of target genes on dried blood spots collected from the NBS cards in a timely and cost-efficient manner, and its high dynamicity allows for any newly treatable rare disease to be included in its scheme in no longer than 6 months.

Baby Detect, as a multidisciplinary newborn screening program, involves expertise in areas from genetics and medicine to laboratory studies, computer science, Data Protection, Ethics, and health economy. It will constitute the proof of concept that is needed before moving to a whole region-scale population.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • newborn between birth and 28 days of life
  • consent of parent

Exclusion criteria

  • + 28 days
  • Non consent of parent

Treatment and study plan

Primary outcomes

  1. Acceptability

    Time frame: through study completion, an average of 1 year

    The percentage of parents accepting the proposed screening in comparison with the number of mothers approached for consent

  2. Feasibility - timing

    Time frame: through study completion, an average of 1 year

    The Turn-around time for the different mutations that are screened

  3. Feasibility - reliability

    Time frame: through study completion, an average of 1 year

    The percentage of false positives and the predicted value for each test The estimation of the false negatives through collaboration with physicians treating the different diseases.

Secondary outcomes

  1. Consequence of NBS on early treatment access - timing

    Time frame: through study completion, an average of 1 year

    The time passed between the birth of diagnostic-positive newborns to the initiation of their treatment

  2. Consequence of NBS on early treatment access - frequency

    Time frame: through study completion, an average of 1 year

    The number of patients offered early treatment

  3. To improve the detection technique for disease related mutations that are not detected in classical screening by improving the classification of unspecified variants.

    Time frame: through study completion, an average of 1 year

    The number of new mutations implemented yearly in the NBS.

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Liege

Other

Collaborators

  • Centre Hospitalier Régional de la Citadelle
  • Leon Fredericq Foundation
  • Orchard Therapeutics
  • Sanofi
  • Takeda
  • University of Liege
  • Zentech-Lacar Company

Registry information

Official study title

Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect

Acronym: BabyDetect

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Jan 18, 2023
Registry last updated
Aug 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.